Full mechanism, in text

Why the injection causes weight loss

1 · The native gut hormone

After a meal, gut L-cells release , which DPP-4 degrades with a half-life of only 1-2 minutes; semaglutide is reshaped to resist this and last a week per injection.The active ingredient in Ozempic / Wegovy, semaglutide, is essentially a hormone your body already makes, pharmacologized. That hormone is (glucagon-like peptide-1).

Where does it come from? After you eat, food (carbohydrate and fat especially) reaches the lower small intestine and colon, stimulating L-cells in the gut wall to secrete GLP-1. It belongs to the incretin family — for the same meal, oral glucose elicits noticeably more insulin than an equal dose given intravenously, and that extra insulin is the gut hormones' doing.

Native GLP-1 has a fatal flaw: a half-life of only 1-2 minutes, rapidly degraded by an enzyme called DPP-4 before it can do much. The drug's whole cleverness is reshaping the molecule to resist degradation and last a week per injection (semaglutide), turning the brief post-meal satiety burst into a signal that does not fade for 24 hours.

That long-acting signal acts in three places at once: the pancreas, the stomach and the brain.

2 · Three targets at once

receptor agonists act on three organs at once: the pancreas amplifies insulin only when glucose is elevated, the stomach empties more slowly, and the brain dampens appetite. receptor agonists work broadly because they act on three organs at once, each riding an independent mechanism:

· Pancreas (glucose control): they stimulate β-cells to release insulin, but crucially in a glucose-dependent way — amplifying insulin only when blood glucose is elevated, not when it is normal. This is why used alone they rarely drive glucose into hypoglycemia, the safety backbone of their use as a diabetes drug. They also suppress glucagon, reducing the liver's loose glucose release.
· Stomach (slowed emptying): they slow gastric emptying, so food lingers longer, physically prolonging fullness and flattening the post-meal glucose spike. This is also the source of nausea and early satiety — two sides of the same mechanism.
· Brain / hypothalamus (central satiety): they act directly on satiety circuits like the arcuate nucleus, raising fullness and lowering appetite. For weight management this pathway is considered dominant — the weight loss comes mainly from eating less, not just nicer glucose numbers.

Three pathways firing together — that is why a glucose drug produces marked weight loss.

3 · Why weight falls — the food noise quiets

After weight loss the brain enters famine mode to pull weight back, and drugs add a long-acting satiety signal from downstream that partly suppresses this defense.Leptin biology sets this up: after weight loss the brain weakens satiety hormones and strengthens hunger hormones, entering famine mode to drag you back to your old weight. What the class does is not repair leptin's jammed loop but supply, from downstream, a long-acting satiety signal that partly suppresses this defense.

The most vivid thing many people report on these drugs is that the food noise goes quiet — that background hum of I just ate and I'm already thinking about the next bite; I can't walk past the bakery settles. That is the subjective feel of a continuously activated central satiety circuit: not forcing yourself to resist, but simply wanting it less.

How large is the effect? STEP 1 (semaglutide) produced ~15% weight loss over 68 weeks; SURMOUNT-1 (tirzepatide, agonizing both GLP-1 and GIP) reached ~21% over 72 weeks, the current pharmacologic ceiling and approaching the magnitude of some bariatric surgery.

Key insight: this is not cheating — it is an admission that set-point defense is real biology that willpower alone won't beat. But it has costs.

4 · The cost — it isn't free

Four costs come with it: most people regain after stopping, digestive side effects are common, part of the loss is muscle, and long-term safety data are still accumulating.Put back into real life, four costs must be stated plainly:

· Stop the drug, regain the weight: it suppresses the symptom (weak satiety signaling), not the cause (set-point defense). On discontinuation the hormones return to post-loss famine mode and most people regain — the STEP 1 extension showed about two-thirds of the lost weight returns within a year of stopping. So it behaves more like a blood-pressure drug: chronic management of a chronic disease, not a course you finish.
· GI side effects: nausea, vomiting, constipation and diarrhea are common — the other face of the slowed gastric emptying mechanism; most ease with time and slow dose escalation, but some people stop because of them.
· Not all of it is fat: any rapid weight loss takes some muscle, and loss is no exception. Without deliberate adequate protein (~1.2-1.6 g/kg) plus resistance training, a meaningful share of the loss is lean mass, which hurts long-term metabolism.
· Long-term unknowns + real barriers: these drugs haven't been around very long, so decades-scale safety data are still accumulating; add cost, access and the need for medical supervision.

It is neither magic nor moral failure — it is a tool with real indications and real costs. Who should use it, and how, is a decision to make with a doctor against the actual indications.

Full mechanism, in text

1 · The native gut hormone

2 · Three targets at once

3 · Why weight falls — the food noise quiets

4 · The cost — it isn't free

GLP-1 — 4-step mechanism

Full mechanism, in text

1 · The native gut hormone

2 · Three targets at once

3 · Why weight falls — the food noise quiets

4 · The cost — it isn't free

GLP-1 — 4-step mechanism